<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04815005</url>
  </required_header>
  <id_info>
    <org_study_id>HICC</org_study_id>
    <nct_id>NCT04815005</nct_id>
  </id_info>
  <brief_title>HoFH, the International Clinical Collaborators Registry</brief_title>
  <acronym>HICC</acronym>
  <official_title>HoFH, the International Clinical Collaborators - A Global HoFH Data-sharing Platform</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Amsterdam</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Cape Town</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Witwatersrand, South Africa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Homozygous familial hypercholesterolemia (HoFH), a rare inherited disorder caused by&#xD;
      bi-allelic mutations in the LDL Receptor pathway, is characterized by extremely elevated&#xD;
      levels of low-density lipoprotein cholesterol (LDL-C) from birth and premature&#xD;
      atherosclerotic cardiovascular disease (ASCVD). Our current knowledge about HoFH is&#xD;
      disjointed and largely stems from relatively small case series and expert opinion. HICC&#xD;
      (Homozygous FH International Clinical Collaborators) is a global consortium of clinicians who&#xD;
      are contributing de-identified data of patients diagnosed with HoFH with the goal to advance&#xD;
      our understanding of this rare disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The HICC registry is an observational, multicenter, international registry collecting&#xD;
      de-identified clinical and genetic information from patients with homozygous Familial&#xD;
      Hypercholesterolemia (HoFH) worldwide.&#xD;
&#xD;
      Patients are eligible to be enrolled in the registry based on the diagnosis of HoFH by the&#xD;
      treating clinician, irrespective of how the diagnosis was made. To generate up-to-date data&#xD;
      reflecting current rather than historic practice, patients who died or were lost to follow-up&#xD;
      prior to 2010 are excluded.&#xD;
&#xD;
      Anonymized data on demographics, type of HoFH diagnosis (clinical and/or based on the results&#xD;
      of a genetic test), genetic results, (cardiovascular) medical history, relevant family&#xD;
      history, physical examination, laboratory measurements, lipid lowering treatment and&#xD;
      cardiovascular imaging are collected for 3 different time points: at diagnosis, at enrolment&#xD;
      and at time of best lipid profile (if this is different from time at enrolment). Data are&#xD;
      collected using pre-definite electronic case report forms to ensure uniformity of data&#xD;
      collected. Primary analysis will be cross-sectional (e.g. based on country of residence, age,&#xD;
      etc)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 24, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>1 Day</target_duration>
  <primary_outcome>
    <measure>Number of participants entered into the database</measure>
    <time_frame>Through study completion, an average of 8 years</time_frame>
    <description>Number of study participants with homozygous familial hypercholesterolemia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Untreated and treated LDL-C levels across world income regions</measure>
    <time_frame>Through study completion, an average of 8 years</time_frame>
    <description>Number of treated versus number of untreated subjects with relevant LDL-C levels</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Homozygous Familial Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>HoFH</arm_group_label>
    <description>Patients diagnosed with HoFH by their physicians, either based on clinical or genetic criteria.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Demographics, diagnosis type, genotype, lipid profile, treatment allocation, country of residence.</intervention_name>
    <description>Differences in diagnosis, genotype, lipid profile treatment allocation among HoFH patients worldwide.</description>
    <arm_group_label>HoFH</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The registry aims to include data from as many patients diagnosed with HoFH as possible.&#xD;
        All patients must be living at time of entry into the database or have been deceased within&#xD;
        the last 5 years.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of homozygous familial hypercholesterolemia (HoFH) clinically of genetically&#xD;
             determined&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No diagnosis of HoFH&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marina Cuchel, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marina Cuchel, MD, PhD</last_name>
    <phone>2156627188</phone>
    <email>mcuchel@pennmedicine.upenn.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lauren Vincent, MRA</last_name>
    <phone>2156155448</phone>
    <email>laurv@pennmedicine.upenn.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marina Cuchel, MD, PhD</last_name>
      <phone>215-662-7188</phone>
      <email>mcuchel@pennmedicine.upenn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lauren Vincent, MRA</last_name>
      <phone>2156155448</phone>
      <email>laurv@pennmedicine.upenn.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Marina Cuchel, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Vascular Medicine, Amsterdam UMC</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>G. Kees Hovingh, MD, PhD</last_name>
      <email>g.k.hovingh@amsterdamumc.nl</email>
    </contact>
    <investigator>
      <last_name>G. Kees Hovingh, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Medicine, Division of Lipidology and Hatter Institute for Cardiovascular Research in Africa, University of Cape Town</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dirk J Blom</last_name>
      <email>dirk.blom@uct.ac.za</email>
    </contact>
    <investigator>
      <last_name>Dirk J Blom</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>c. Carbohydrate and Lipid Metabolism Research Unit, Faculty of Health Sciences, University of Witwatersrand</name>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frederick J Raal</last_name>
      <email>frederick.raal@wits.ac.za</email>
    </contact>
    <investigator>
      <last_name>Frederick J Raal, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>South Africa</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 4, 2021</study_first_submitted>
  <study_first_submitted_qc>March 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2021</study_first_posted>
  <last_update_submitted>June 15, 2021</last_update_submitted>
  <last_update_submitted_qc>June 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Homozygous Familial Hypercholesterolemia</keyword>
  <keyword>Autosomal Dominant</keyword>
  <keyword>Hypercholesterolemia</keyword>
  <keyword>Autosomal Recessive Hypercholesterolemia</keyword>
  <keyword>Registry</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipoproteinemia Type II</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

